(Reuters) - U.S. regulators have approved Johnson & Johnson's Sedasys system to sedate patients during colonoscopies without the need for a physician to monitor delivery of the injectable sedating agent, the company said on Friday.
The device uses propofol, which is already widely used in colonoscopy procedures.
The system reduces the risks of oversedation when compared to other traditional methods, Johnson & Johnson said in a release, with 99% of patients recovering from the effects within 10 minutes after administration of the drug.
J&J said the system is expected to be introduced on a limited basis beginning in 2014.
The company estimates that 15 million patients in the United States are candidates for these procedures.